SWTX

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SWTX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/08	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/06/06	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/06/05	20 : 00	GlobeNewswire Inc.	SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/06/04	05 : 37	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/05/24	06 : 13	GlobeNewswire Inc.	SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/05/18	05 : 53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/05/08	20 : 00	GlobeNewswire Inc.	SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/05/02	19 : 30	GlobeNewswire Inc.	SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/04/25	02 : 31	GlobeNewswire Inc.	SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/04/18	20 : 00	GlobeNewswire Inc.	SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/03/04	20 : 30	GlobeNewswire Inc.	SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/03/02	07 : 16	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/29	22 : 30	GlobeNewswire Inc.	SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	22 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	22 : 23	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	21 : 29	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	20 : 51	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	20 : 44	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/27	20 : 30	GlobeNewswire Inc.	SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/22	21 : 00	GlobeNewswire Inc.	SpringWorks Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/21	08 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/17	03 : 09	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/14	22 : 56	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/06	11 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/06	11 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/03	06 : 38	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/02/03	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/01/31	21 : 00	GlobeNewswire Inc.	SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/01/09	11 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc
2024/01/09	11 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SWTX	SpringWorks Therapeutics Inc